Press Room

Press Clipping / Feb 17, 2022

Seven Companies in Ireland achieve the Business Working Responsibly mark with a further ten recertifying to the standard

BITCI Ireland, 17 February 2022

Business Working Responsibility Mark logo | Hovione
  • The Mark is operated by Business in the Community Ireland (BITCI), the non-profit organisation dedicated to sustainability and third-party audited by the National Standards Authority of Ireland (NSAI).
  • Seven companies achieved the Mark for the first time with another ten achieving recertification.
     
  •  

  •  

Press Release Thursday 17th February:  Over 200 business leaders attended Business in the Community Ireland’s virtual celebration event where the latest companies certified to the Business Working Responsibly mark in 2021/2022 were announced.

The Mark which is run by Business in the Community Ireland and based on ISO 26000 is valid for three years and is independently audited by the National Standards Authority of Ireland (NSAI).

Seven companies are being accredited to the Mark for the first time this year and they are Alkermes, An Post, Grant Thornton Ireland, Iarnród Éireann – Irish Rail, Ornua, Vermilion and William Fry.

In addition, ten companies achieved recertification to the Mark and they are Boots (Retail) Ireland Ltd, BT Ireland, Central Bank of Ireland, CRH Operating Companies in Ireland, Deloitte Ireland, Gas Networks Ireland, HEINEKEN Ireland, Hovione, Intel Ireland and Sodexo Ireland. 46 companies in Ireland have now achieved the sustainability standard.

The Mark  looks at leadership, policies, practices, performance and impact in areas such as employee wellbeing, diversity and inclusion, environmental practices, supply chain management and engagement with the local community.

For more details on our sustainability standard, visit the Business Working Responsibly mark section of our website. 

 

Read the full article on BITC.ie

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026